Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.
Intraperitoneal chemotherapy prolongs survival of ovarian cancer patients, but its utility is limited by treatment-related complications and inadequate drug penetration in larger tumors. Previous intraperitoneal therapy used the paclitaxel/Cremophor EL (polyethoxylated castor oil) formulation designed for intravenous use. The present report describes the development of paclitaxel-loaded microparticles designed for intraperitoneal treatment (referred to as tumor-penetrating microparticles or TPM). Evaluation of TPM was performed using intraperitoneal metastatic, human ovarian SKOV3 xenograft tumor models in mice. TPM were retained in the peritoneal cavity and adhered to tumor surface. TPM consisted of two biocompatible and biodegradable polymeric components with different drug release rates; one component released the drug load rapidly to induce tumor priming, whereas the second component provided sustained drug release. Tumor priming, by expanding interstitial space, promoted transport and penetration of particulates in tumors. These combined features resulted in the following advantages over paclitaxel/Cremophor EL: greater tumor targeting (16-times higher and more sustained concentration in omental tumors), lower toxicity to intestinal crypts and less body weight loss, greater therapeutic efficacy (longer survival and higher cure rate), and greater convenience (less frequent dosing). TPM may overcome the toxicities and compliance-related problems that have limited the utility of intraperitoneal therapy.
Lu
Ze
Z
Optimum Therapeutics, LLC, Columbus, Ohio, USA.
Tsai
Max
M
Lu
Dan
D
Wang
Jie
J
Wientjes
M Guillaume
MG
Au
Jessie L-S
JL
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000633:toxicity; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007700:Kinetics; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000633:toxicity; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000972:Antineoplastic Agents, Phytogenic; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D017239:Paclitaxel
Cancer Res. 1987 Mar 15;47(6):1712-6
3815369
J Pharmacol Exp Ther. 2001 Mar;296(3):1035-42
11181938
N Engl J Med. 2006 Apr 13;354(15):1641-3; author reply 1641-3
16611959
Cancer Res. 1988 Oct 15;48(20):5874-7
3167842
Acta Cytol. 1996 May-Jun;40(3):429-36
8669174
Cancer Surv. 1993;17:105-22
8137338
Cancer Res. 1991 Apr 15;51(8):2041-6
2009523
J Clin Oncol. 1998 Aug;16(8):2620-4
9704711
AAPS PharmSci. 2001;3(2):E15
11741266
J Biomed Mater Res A. 2006 May;77(2):351-61
16425240
Pharm Res. 2002 Apr;19(4):411-7
12033372
Tumori. 1985 Feb 28;71(1):63-8
3984048
Adv Drug Deliv Rev. 1997 Oct 13;28(1):5-24
10837562
Semin Oncol. 1988 Jun;15(3 Suppl 4):27-31
3134695
Ann Intern Med. 1984 Jul;101(1):14-8
6732077
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901
14676112
Invest New Drugs. 2001 May;19(2):113-23
11392446
Surg Oncol Clin N Am. 2003 Jul;12(3):755-69, xiv
14567029
J Clin Oncol. 2006 Feb 20;24(6):988-94
16461779
J Pharmacol Exp Ther. 2007 Jul;322(1):80-8
17420296
Gynecol Oncol. 2000 Feb;76(2):157-62
10637064
Gynecol Oncol. 2006 Nov;103(2):391-6
16626792
N Engl J Med. 1996 Dec 26;335(26):1950-5
8960474
J Biomed Mater Res. 1985 Mar;19(3):349-65
4077887
Anticancer Drug Des. 1990 Nov;5(4):359-69
2127181
J Clin Oncol. 2001 Feb 15;19(4):1001-7
11181662
Cancer Res. 1996 May 1;56(9):2086-93
8616855
J Chromatogr B Biomed Appl. 1995 Jan 20;663(2):337-44
7735481
Pharm Res. 2007 Sep;24(9):1691-701
17447121
Cancer Chemother Pharmacol. 1990;25(6):389-94
2311166
J Pharmacol Exp Ther. 1999 Aug;290(2):871-80
10411604
Cancer Chemother Pharmacol. 1991;28(3):159-65
1855272
Clin Cancer Res. 1998 Feb;4(2):277-82
9516911
Eur J Gynaecol Oncol. 1998;19(3):265-70
9641228
J Clin Oncol. 2007 Feb 1;25(4):437-43
17264340
J Clin Oncol. 1992 Sep;10(9):1485-91
1355523
Gynecol Oncol. 1993 Jul;50(1):100-4
8349150
Cancer Res. 1999 Aug 1;59(15):3776-82
10446995
N Engl J Med. 2006 Jan 5;354(1):34-43
16394300